EXCEDE, DRAXXIN Receive FDA Approval to Treat Foot Rot

November 6, 2008 12:50 PM
            Dairy producers have a new option to treat one of the leading causes of lameness in dairy cattle—foot rot. Pfizer Animal Health's EXCEDE® (ceftiofur crystalline free acid) Sterile Suspension has received approval from the U.S. Food and Drug Administration for the treatment of foot rot.
            Producers now have the flexibility to make management adjustments based on labor or market factors. "A single dose of EXCEDE works with a lactating cow's immune system to treat disease without repeated administration or changing medication,” said Jessica Light, DVM, senior veterinarian for Pfizer Animal Health.
            EXCEDE provides treatment of bovine foot rot associated with Fusobacterium necrophorum and Porphyromonas levii. Symptoms usually occur within 24 hours to 5 days of the onset of infection. Vigilance is important, because untreated foot rot can lead to lameness, downer cows and culling. It is extremely critical to treat foot rot early to prevent the condition from worsening.
            The addition of foot rot to the EXCEDE label expands its worth to the producer even more. EXCEDE already provides broad-spectrum efficacy against bovine respiratory disease (BRD) and its unique base of ear administration.
            In addition, DRAXXIN® (tulathromycin) Injectable Solution, for use in dairy cattle up to 20 months of age, is now a viable option for foot rot treatment, following recent U.S. Food and Drug Administration approval. Adding yet another use to the anti-infective's already broad portfolio, DRAXXIN treats foot rot caused by the bacteria Fusobacterium necrophorum and Porphyromonas levii.
            With the current value of calves and replacement heifers, dairy producers understand the importance of getting them off to a healthy start. DRAXXIN gives producers the broad-spectrum treatment they need with one convenient dose to ensure a healthy start that leads to a lifetime of high quality milk production.
            DRAXXIN is currently the only anti-infective approved for the treatment and control of bovine respiratory disease (BRD), or calf pneumonia, caused by all four major BRD pathogens—including Mannheimia haemolytica, Pasteurella multocida, Histophilus somni and Mycoplasma bovis. Pneumonia can compromise a calf's ability to produce at peak levels later in life. DRAXXIN also treats pink eye (infectious bovine keratoconjunctivitis) associated with Moraxella bovis in nonlactating dairy cattle.
            For more information, visit www.PfizerAH.com.

Back to news



Spell Check

No comments have been posted to this News Article

Corn College TV Education Series


Get nearly 8 hours of educational video with Farm Journal's top agronomists. Produced in the field and neatly organized by topic, from spring prep to post-harvest. Order now!


Market Data provided by QTInfo.com
Brought to you by Beyer